Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc gamma RI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer

Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):207-9. doi: 10.1007/s002620050434.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antibodies, Bispecific / blood
  • Antibodies, Bispecific / therapeutic use*
  • Breast Neoplasms / blood
  • Breast Neoplasms / immunology
  • Breast Neoplasms / pathology
  • Breast Neoplasms / therapy*
  • Female
  • Filgrastim
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Humans
  • Middle Aged
  • Receptor, ErbB-2 / immunology*
  • Receptors, IgG / immunology*
  • Recombinant Proteins

Substances

  • Antibodies, Bispecific
  • Receptors, IgG
  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor
  • Receptor, ErbB-2
  • Filgrastim